Visirna Therapeutics Hk Limited
Clinical trials sponsored by Visirna Therapeutics Hk Limited, explained in plain language.
-
New RNAi drug shows promise for rare, severe high cholesterol
Disease control OngoingThis study tests an experimental RNAi drug called VSA003 in 46 Chinese adolescents and adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol and early heart disease. The drug aims to lower harmful cholesterol by b…
Phase: PHASE3 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New siRNA drug aims to halt liver damage in NASH patients
Disease control OngoingThis study tests an experimental drug called VSA006 in 48 Chinese adults with NASH, a type of fatty liver disease that can lead to scarring. The drug works by targeting a gene linked to liver protection. Researchers want to see if it can improve liver health and reduce fat withou…
Phase: PHASE2 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated May 26, 2026 08:32 UTC